Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Apr;59(4):2474.
doi: 10.1128/AAC.05173-14.

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future

Marieke G G Sturkenboom  1 , Onno W Akkerman  2 , Mathieu S Bolhuis  1 , Wiel C M de Lange  2 , Tjip S van der Werf  3 , Jan-Willem C Alffenaar  4
Affiliations
Comment

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future

Marieke G G Sturkenboom et al. Antimicrob Agents Chemother. 2015 Apr.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Requena-Mendez A, Davies G, Waterhouse D, Ardrey A, Jave O, Lopez-Romero SL, Ward SA, Moore DA. 2014. Effect of dosage, co-morbidities and food on pharmacokinetics of isoniazid in Peruvian TB patients. Antimicrob Agents Chemother 58:7164–7170. doi:10.1128/AAC.03258-14. - DOI - PMC - PubMed
    1. Prahl JB, Johansen IS, Cohen AS, Frimodt-Moller N, Andersen AB. 2014. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother 69:2841–2847. doi:10.1093/jac/dku210. - DOI - PubMed
    1. Pasipanodya JG, Srivastava S, Gumbo T. 2015. Comment on: clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother 70:320–321. doi:10.1093/jac/dku345. - DOI - PubMed
    1. Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE. 2014. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents 44:229–234. doi:10.1016/j.ijantimicag.2014.04.019. - DOI - PubMed
    1. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. 2011. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 17:2931–2939. doi:10.2174/138161211797470174. - DOI - PubMed